Quality assurance initiative for systemic treatment in metastatic colorectal cancer

Quality assurance initiative for systemic treatment in metastatic colorectal cancer - QA-mCRC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00033377

Enrollment

2100

Registered

2024-04-09

Start date

2025-02-25

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C18 C19 C20

Interventions

Group 1: 1st line: Diagnosis of mCRC with primarily non-resectable metastases in QIII/23 and QIV/23

1st line systemic therapy in the metastatic setting Group 2: 2nd line patients: Treatment decision on a 2nd line system therapy in QIII/23 and QIV/23

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of mCRC with primarily non-resectable metastases in QIII/23 and QIV/23 and 1st line systemic treatment or 2nd line systemic treatment therapy in the metastatic setting

Exclusion criteria

Exclusion criteria: Patients with non-metastatic disease Patients with only primarily resectable metastases Patients are not suitable for systemic therapy due to reduced general condition or concomitant diseases

Design outcomes

Primary

Measure	Time frame
Implementation of the guideline recommendations in routine treatment	—

Secondary

Measure	Time frame
The demographic and clinical characteristics of patients in first- and second-line therapy The establishment of liquid biopsy in clinical routine	—

Countries

Germany

Contacts

Public ContactMarkus Kerkmann

MMF Research GmbH

crc@mmf-research.de+49 251 928730 19

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026